Psoriatic Arthritis Resource Center

Psoriatic arthritis (PsA) is distinguished from other forms of inflammatory arthritis by unique pathophysiology and manifestations. Important developments for rheumatologists and rheumatology professionals to note include the release of a PsA treatment guideline in early 2019, the development of patient outcome measures and studies that have demonstrated that tight control of disease activity leads to improvements in these outcome measures for patients. In this resource center, you’ll find our summary of the guideline, as well as a collection of important research reviews, case reports and clinical articles on advances in the diagnosis and management of PsA.

FEATURED ARTICLE: Imaging of Axial Psoriatic Arthritis

Reproductive Health & PsA: New ACR Training Program Enhances Provider Education

The ACR has developed educational materials for healthcare providers to use to discuss reproductive health and contraception with their patients with psoriatic arthritis.... [Read More]

New Supplement to The Rheumatologist Highlights Psoriatic Arthritis Advances

It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely… [Read More]

Minimizing Disease Activity in Psoriatic Arthritis

The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and… [Read More]

A Dematologist’s Perspective on Choosing an Anti-Psoriatic Drug

We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox… [Read More]

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib… [Read More]

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and… [Read More]

Psoriatic Arthritis Treatment Update

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA… [Read More]

The Latest Psoriatic Arthritis Management Insights

An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater… [Read More]

Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis

Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to… [Read More]

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.... [Read More]